FDMT Q3 2023 Earnings — 4D Molecular Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FDMT4D Molecular Therapeutics, Inc.

$468M

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$20M+3940.8% YoY

Gross Profit

-$5M-24.1% margin

Operating Income

-$14M-69.2% margin

Net Income

-$10M-50.8% margin

EPS (Diluted)

$-0.24

QoQ Revenue Growth

+8353.6%

Cash Flow

Operating Cash Flow

-$1M

Free Cash Flow

-$2M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$362M

Total Liabilities

$32M

Stockholders' Equity

$330M

Cash & Equivalents

$276M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$20M	$500,000	+3940.8%
Gross Profit	-$5M	-$18M	+73.6%
Operating Income	-$14M	-$26M	+47.3%
Net Income	-$10M	-$26M	+60.1%

Geographic Segments

UNITED STATES

$20M100%

NETHERLANDS

$41,0000%